Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial
- 28 July 2006
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 368 (9532), 287-298
- https://doi.org/10.1016/s0140-6736(06)69074-0
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- British HIV Association (BHIVA) guidelines for the treatment of HIV‐infected adults with antiretroviral therapy (2005)HIV Medicine, 2005
- Treatment for Adult HIV InfectionJAMA, 2004
- Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 InfectionThe New England Journal of Medicine, 2003
- Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 InfectionThe New England Journal of Medicine, 2003
- Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV InfectionThe New England Journal of Medicine, 2002
- An Open-Label Randomized Trial to Evaluate Different Therapeutic Strategies of Combination Therapy in HIV-1 Infection: Design, Rationale, and Methods of the Initio TrialControlled Clinical Trials, 2001
- The Rationale and Design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) TrialControlled Clinical Trials, 2001
- 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individualsThe Lancet, 1998